The FDA recently approved Otsuka Pharmaceutical’s Abilify MyCite for certain psychiatric conditions. No big whoop, other than it’s the first digital pill approved by the FDA. The pill has a sensor, called an Ingestible Event Marker (IEM) sensor, that wirelessly connects to a patch (developed by Proteus) worn on the torso, which gathers additional data before transmitting it to a phone app. So, what is the big whoop? You probably already got there but think “medication adherence.” According to this NIH paper, $100-$300 billion of avoidable health care costs have been attributed to nonadherence in the US annually, representing 3% to 10% of total US health care costs. Another angle, digital pills could become very “sticky” with patients and providers, potentially locking in revenue for pharma companies. Speaking of a “win-win” go here to get InsightCity’s first Buzzword Bingo card (it’ll be a collector’s item soon).